LENVIMA is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC).
LENVIMA: Efficacy that drives results1
Offering more time without disease progression1
CI=confidence interval; NE=not estimable; PFS=progression-free survival; HR=hazard ratio; AR=adverse reaction.